Dr. Brian Czerniecki, MD, PhD.

Dept Chair of Breast Oncology, Moffitt Cancer Center &
Professor Emeritus of the University of Pennsylvania

Dr. Brian Czerniecki is Chair and Senior Member in the Moffitt Cancer Center Department of Breast Oncology. Dr. Czerniecki received his BS in Biochemistry from the University of Maine and his MD from the University of Medicine and Dentistry of New Jersey (UMDNJ), Robert Wood Johnson Medical School, and his PhD from UMDNJ-Robert Wood Johnson and Rutgers University.
Dr. Czerniecki completed his general surgical residency at The Ohio State University and was Surgical Oncology Fellow at the NCI with Dr. Steven Rosenberg prior to his position at the University of Pennsylvania, Philadelphia.While at the University of Pennsylvania, Dr. Czerniecki served as Professor of Surgery, Perelman School of Medicine; Attending Surgeon, Department of Surgery, Hospital of the University of Pennsylvania; and Co-Director of the Rena Rowan Breast Center–Recruitment and Center Expansion. His research interests focus on dendritic cell biology and interactions with T cells. He has developed dendritic cell vaccines for the treatment of cancer.

He is involved with several clinical trials for treating patients with early breast cancer with dendritic cell vaccines. Dr. Czerniecki’s research goal is the development of vaccines for the prevention of breast and other solid-tumor cancers. Toward that end, he is working on identifying molecular targets in early breast cancer that can be used to prevent invasion and metastasis. Dr. Czerniecki has more than 100 publications and is recognized nationally for his contribution to the development of sentinel lymph node mapping, a procedure for determining the spread of cancer into lymph nodes that is less invasive than diagnostic surgery.

Journals & Publications

Dr. Czerniecki has more than 100 publications and is recognized nationally for his contribution to the development of sentinel lymph node mapping, a procedure for determining the spread of cancer into lymph nodes that is less invasive than diagnostic surgery.

Moffitt welcomes Dr. Brian Czerniecki

Interview from the first trial of the vaccine

Oncology Times  Dendritic Cell Vaccine Induces Strong Immune Response Against DCIS    

Cancer Review

Development of Vaccines for High-Risk Ductal Carcinoma In situ of the Breast  

Cancer Review

Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with   Staged Interleukin-12 Burst Secretion

Other Peer-Reviewed Publications, Click Here

Previously Conducted CLINICAL TRIALS by Number below, PLEASE CONTACT MOFFITT CANCER CENTER for their latest Non-Toxic Dendritic Cell Cancer Immunotherapy Trials Available for Patient Participation

CLINICAL TRIAL 19337

A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer

Condition: Breast
Intervention: DC1 Vaccine; Herceptin (Trastuzumab); Paraplatin (carboplatin); Pertuzumab; Taxotere (docetaxel); Trastuzumab;
carboplatin; docetaxel; rhuMAb HER2 (Trastuzumab)
Open

OTHER NON-VACCINE RELATED TRIALS

CLINICAL TRIAL 18386

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Condition: Breast
Intervention: Not Applicable Open

CLINICAL TRIAL 18936

A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer

Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 19237

An Open-Label, Single-Arm, Phase 2 Study Of Avb-620 In Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Condition: Breast
Intervention: AVB-620

CLINICAL TRIAL 19755

A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination with Intravenous Pembrolizumab Therapy in Patients with Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer

Condition: Breast
Intervention: Pembrolizumab (Keytruda); tavo-EP

CLINICAL TRIAL 18621

A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Condition: Breast
Intervention: Adriamycin (doxorubicin); Nab-paclitaxel (Abraxane); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel

CLINICAL TRIAL 19765

Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

Condition: Breast
Intervention: BMS-936558 (Nivolumab); Nivolumab

CLINICAL TRIAL 18596

A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy

Condition: Breast
Intervention: Not Applicable